DrugPatentWatch Database Preview

Gemini Labs Llc Company Profile

« Back to Dashboard

What is the competitive landscape for GEMINI LABS LLC, and what generic and branded alternatives to GEMINI LABS LLC drugs are available?

GEMINI LABS LLC has two approved drugs.

Summary for Gemini Labs Llc

US Patents:	0
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Gemini Labs Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-002	Nov 5, 2001		DISCN	Yes	No
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-003	Dec 22, 1997		DISCN	Yes	No
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-002	Dec 22, 1997		DISCN	Yes	No
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-001	Dec 22, 1997		DISCN	Yes	No

Expired US Patents for Gemini Labs Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-003	Dec 22, 1997	5,312,924
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-001	Dec 22, 1997	6,143,769
Gemini Labs Llc	PRANDIN	repaglinide	TABLET;ORAL	020741-002	Dec 22, 1997	5,216,007
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-001	Approved Prior to Jan 1, 1982	5,872,147
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-001	Approved Prior to Jan 1, 1982	6,670,351
Gemini Labs Llc	OXANDRIN	oxandrolone	TABLET;ORAL	013718-002	Nov 5, 2001	6,670,351

Paragraph IV (Patent) Challenges for GEMINI LABS LLC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.5 mg, 1 mg and 2 mg		2005-02-10
	Tablets	2.5 mg and 10 mg		2006-06-19

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Gemini Labs Llc